SCI Pharmtech Management
Management criteria checks 1/4
SCI Pharmtech's CEO is Wen-Chih Chou, appointed in Jun 2022, has a tenure of 2.42 years. directly owns 0.17% of the company’s shares, worth NT$20.06M. The average tenure of the management team and the board of directors is 1.9 years and 11.4 years respectively.
Key information
Wen-Chih Chou
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.9yrs |
| Board average tenure | 11.4yrs |
Recent management updates
Recent updates
Shareholders Shouldn’t Be Too Comfortable With SCI Pharmtech's (TWSE:4119) Strong Earnings
Nov 17
We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings
Mar 27Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates
Apr 07There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings
Mar 30SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?
Mar 08SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years
Jan 25
Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates
Dec 30Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?
Dec 29Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?
Dec 08A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | NT$484m |
| Jun 30 2024 | n/a | n/a | NT$138m |
| Mar 31 2024 | n/a | n/a | NT$276m |
| Dec 31 2023 | n/a | n/a | NT$295m |
| Sep 30 2023 | n/a | n/a | NT$377m |
| Jun 30 2023 | n/a | n/a | NT$390m |
| Mar 31 2023 | n/a | n/a | NT$331m |
| Dec 31 2022 | NT$6m | NT$4m | NT$309m |
| Sep 30 2022 | n/a | n/a | NT$210m |
| Jun 30 2022 | n/a | n/a | NT$192m |
| Mar 31 2022 | n/a | n/a | NT$55m |
| Dec 31 2021 | NT$3m | NT$2m | NT$56m |
Compensation vs Market: Insufficient data to establish whether Wen-Chih's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Wen-Chih's compensation has increased by more than 20% in the past year.
CEO
Wen-Chih Chou
2.4yrs
Tenure
NT$5,623,386
Compensation
Mr. Wen-Chih Chou serves as Director & GM at SCI Pharmtech, Inc. since December 17, 2001 and also serves as it's President from July 2022 and was its Plant Manager since September 01, 2009 until July 2022....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.4yrs | NT$5.62m | 0.17% NT$ 20.1m | |
| Vice President of F&A Div. | 21.8yrs | no data | no data | |
| Assistant Vice President of Operating Div. | 1.3yrs | no data | no data | |
| Vice President of Technical Div. | 1.3yrs | no data | no data | |
| Sustainable Environment Team Manager & PDM/EH Manager | no data | no data | no data |
1.9yrs
Average Tenure
Experienced Management: 4119's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 22.9yrs | NT$5.62m | 0.17% NT$ 20.1m | |
| Director | 22.9yrs | NT$330.00k | no data | |
| Independent Director | 9.4yrs | NT$810.00k | no data | |
| Chairman | 22.9yrs | NT$7.50m | 0.62% NT$ 72.1m | |
| Independent Director | 11.4yrs | NT$760.00k | no data | |
| Representative Director | less than a year | no data | 0.0042% NT$ 487.1k | |
| Independent Director | 2.4yrs | NT$580.00k | 0.045% NT$ 5.3m |
11.4yrs
Average Tenure
62yo
Average Age
Experienced Board: 4119's board of directors are seasoned and experienced ( 11.4 years average tenure).